Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Common Equity (2021 - 2025)

Historic Common Equity for Coeptis Therapeutics Holdings (COEPW) over the last 5 years, with Q3 2025 value amounting to $10.9 million.

  • Coeptis Therapeutics Holdings' Common Equity rose 11910.61% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year increase of 11910.61%. This contributed to the annual value of $3.9 million for FY2024, which is 37511.02% up from last year.
  • As of Q3 2025, Coeptis Therapeutics Holdings' Common Equity stood at $10.9 million, which was up 11910.61% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' Common Equity ranged from a high of $10.9 million in Q3 2025 and a low of -$5.6 million during Q3 2021
  • For the 5-year period, Coeptis Therapeutics Holdings' Common Equity averaged around $3.2 million, with its median value being $2.4 million (2021).
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 23476.2% in 2024, then soared by 238347.09% in 2025.
  • Coeptis Therapeutics Holdings' Common Equity (Quarter) stood at $2.4 million in 2021, then skyrocketed by 89.45% to $4.5 million in 2022, then plummeted by 81.72% to $813964.0 in 2023, then soared by 375.11% to $3.9 million in 2024, then skyrocketed by 182.29% to $10.9 million in 2025.
  • Its Common Equity stands at $10.9 million for Q3 2025, versus $7.1 million for Q2 2025 and $7.5 million for Q1 2025.